Regeneron Antibodies Prevent Symptomatic COVID-19 In Interim Phase III Data
Efficacy Data On Casirivimab/Imdevimab In Mutant Strains Forthcoming
The company said data show a lower overall infection rate and no symptomatic infections among participants receiving the drug, compared with placebo.
